ArticleHistochemistry and cell biology2026
FANCD2 promotes wound healing through DNMT1.
Article in Histochemistry and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Fanconi anemia (FA) is primarily an autosomal recessive genetic disorder that leads to bone marrow failure, increased risk of developing cancer, and a plethora of developmental abnormalities. Patients are prone to recurrent infections and increased risk of hemorrhage, as well as delayed wound healing with poor results. FA is caused by a genetic mutation in the proteins needed for FA pathway activation; FA group D2 protein (FANCD2) is an indispensable part of this pathway and plays essential roles in some aspects of cellular life, especially in the cellular responses to DNA damage. Here, we found that depletion of FANCD2 induced reduction of proliferation and migration of NIH3T3 cells. Moreover, FANCD2 knockout decreased production of extracellular matrix (ECM) protein collagen III and cytoskeleton protein alpha-smooth muscle actin (α-SMA). In this process, FANCD2 knockout decreased the expression of DNA methyltransferase 1 (DNMT1), and DNMT1 inhibitor 5-aza-2'-deoxycytidine (5-AZA-CdR) also induced the decline of proliferation and migration ability of NIH3T3 cells, and reduced the expression of collagen III and α-SMA. These findings suggest that FANCD2 affects wound healing through DNMT1. These findings may provide novel therapeutic ideas for clinical treatment of patients with FA with poor wound healing.
Indexed as
Identifiers
41528517What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.